Applications of Cell Signaling and Epigenome Regulation in Cancer Treatment

Dear Colleagues,

Epigenetics is one of the most promising biomedical fields, and the discoveries regarding its implications in health and disease have not stopped. Biomedical and translational evidence suggests that epigenetic alterations (DNA methylation, non-coding RNA expression, and histone modifications) that occur after external stimulation may contribute to the risk of suffering from several diseases, including cancer.

The field of epigenetics has moved from DNA methylation and non-coding RNA expression to a variety of histone modifications. Most importantly, mutations in the epigenetic regulatory molecules have been discovered and the first epigenetic drugs for leukemia and lymphoma treatment have been developed. Therefore, this Special Issue will focus on the field of cancer epigenome regulation and cell signaling that has reached mainstream tumor biology in the development of new biomarkers of cancer and new therapeutic strategies for treatment.

This Special Issue on “Applications of Cell Signaling and Epigenome Regulation in Cancer Treatment” aims to explore applications of cell signaling and epigenome regulation to address cancer cell signaling, progression, metastasis, drug resistance, and therapeutic treatment. Topics include, but are not limited to:

• The exploration of new signaling pathways in cancer;
• The exploration of new tumor epigenomes and epigenetic regulations;
• The study of biomarkers, epigenetic alterations (DNA, RNA, histones), or epigenetic regulatory molecule polymorphisms for tumor therapeutic strategies or prediction;
• The development of tumor-specific models to guide personalized medicine.

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Processes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cell signaling
• epigenome
• epigenetic
• therapeutic treatment
• cancer progression
• metastasis
• drug resistance
• personalized medicine